Latest Morning Briefing Stories
Florida’s Canada Drug Importation Plan Has Yet to Launch
Florida Gov. Ron DeSantis (R) spent years complaining that the Biden administration was slow-walking federal approval of his plan to import lower-cost prescription drugs from Canada — a concept endorsed by Donald Trump in 2020 just before his first presidential term ended. But nearly a year since the Food and Drug Administration green-lit the state’s […]
Who Gets Obesity Drugs Covered by Insurance? In North Carolina, It Helps If You’re on Medicaid
GLP-1 agonist medications such as Ozempic accounted for 10% of the North Carolina state employee health plan’s prescription drug spending, so the state is no longer covering them for weight loss alone. Still, it did decide to cover them for Medicaid patients’ weight loss. A look inside the state’s coverage calculus.
¿Podrían los nuevos medicamentos para bajar de peso estar disponibles para todos?
Los medicamentos agonistas GLP-1, conocidos por los nombres comerciales Ozempic, Trulicity y Wegovy, han demostrado ser efectivos para la pérdida de peso y para el manejo de la diabetes tipo 2.
Florida Gov. DeSantis’ Canadian Drug Import Plan Goes Nowhere After FDA Approval
Florida sued the FDA over what it said was a “reckless delay” in approving its drug importation plan. Now, nearly a year after the FDA gave the state the green light, the program has yet to begin.
El plan del gobernador de Florida para importar medicamentos más baratos de Canadá sigue en la nada
Florida solicitó crear un programa de importación en noviembre de 2020, pocos meses después que la administración Trump concediera esta opción a los estados.
Listen: A Tussle With a Rattlesnake Can Take a Bite Out of Your Wallet
Listen to KFF Health News’ Jackie Fortiér recount how a backyard snakebite led to a harrowing hospitalization — and big bills — for a San Diego family.
No Evidence Trump’s Drug Program for Terminal Patients Saved ‘Thousands’ of Lives
Though the former president has repeatedly hyped the impact of his experimental drug program, there’s no basis for his claims in government data, and medical experts say he’s exaggerating.
What’s at Stake: A Pivotal Election for Six Big Health Issues
Health care has ebbed and surged as an election issue throughout the presidential campaign. Here are the ways some of the most consequential changes in health policies could hinge on whether Vice President Kamala Harris or former President Donald Trump wins.
Beneficiarios de Medicare gastarán menos en medicamentos en 2025
El período de inscripción anual para que los beneficiarios de Medicare renueven o cambien su cobertura de medicamentos, o elijan un plan Medicare Advantage, comenzó el 15 de octubre y se extiende hasta el 7 de diciembre.
Medicare Drug Plans Are Getting Better Next Year. Some Will Also Cost More.
Every year, Medicare officials encourage beneficiaries to shop around for their drug coverage. Few take the time. This year, it might be more important than ever.
Journalists Address Opioid Settlements, Undiagnosed ADHD, and a Georgia Chemical Fire
KFF Health News and California Healthline staff made the rounds on national and local media in the last two weeks to discuss topical stories. Here’s a collection of their appearances.
California Continues Progressive Policies, With Restraint, in Divisive Election Year
This legislative cycle, Gov. Gavin Newsom signed bills affirming reproductive rights and mandating insurance coverage of in vitro fertilization, but the Democrat was reluctant to impose new regulations and frequently cited costs for vetoing bills.
Helene and CVS Land Double Whammy for 25,000 Patients Who Survive on IV Nutrition
A Massachusetts woman ended up stranded in the hospital because CVS stopped providing the IV nutrition she needs to survive at home. Without it, she’d starve.
Colorado’s Naloxone Fund Is Drying Up, Even as Opioid Settlement Money Rolls In
Since Colorado created a pool of money to pay for naloxone in 2019, it has distributed more than half a million doses of the opioid reversal drug to hundreds of organizations throughout the state. Now, its main funding stream is drying up.
KFF Health News' 'What the Health?': Yet Another Promise for Long-Term Care Coverage
As part of her presidential campaign, Vice President Kamala Harris has rolled out a plan for Medicare to provide in-home long-term care services. The proposal would fill a longtime need for families trying to simultaneously care for young children and older parents, but its enormous price tag makes it a promise unlikely to be fulfilled. Meanwhile, a growing number of Republican candidates up and down the ballot facing voter backlash over their support for abortion restrictions are trying to reinvent their positions. Shefali Luthra of The 19th, Jessie Hellmann of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, excerpts from a KFF lunch with “Shark Tank” panelist and generic drug discounter Mark Cuban, who has been consulting with the Harris campaign about health care issues.
Employers Haven’t a Clue How Their Drug Benefits Are Managed
The Big Three pharmacy benefit managers say they return nearly all the rebates they get from drugmakers to the employers and insurers who hire them. But most employers seem to doubt that.
Calif. Ballot Measure Targets Drug Discount Program Spending
Californians in November will weigh in on a ballot initiative to increase scrutiny over the use of health-care dollars — particularly money from a federal drug discount program — meant to support patient care largely for low-income or indigent people. The revenue is sometimes used to address housing instability and homelessness among vulnerable patient populations. Voters […]
What’s New and What To Watch For in the Upcoming ACA Open Enrollment Period
This year’s start date in most states is Nov. 1, and consumers may encounter new scams as well as important rule changes.
Harris Correct That Trump Fell Short on Promise To Negotiate Medicare Drug Prices
The former president instead favored a temporary model that could’ve brought down prices of some prescription drugs, but it was blocked by the courts.
Setting the Record Straight on the FDA’s Authority Over Drug Ads
KFF Health News gives readers a chance to comment on a recent batch of stories.
